Appropriate use of meaningful within-patient change (MWPC) thresholds in Alzheimer's disease
Alzheimers Dement
.
2024 Dec 18.
doi: 10.1002/alz.14436.
Online ahead of print.
Authors
Claire J Lansdall
1
,
Jeffrey L Cummings
2
,
Jeffrey Scott Andrews
3
Affiliations
1
Global Evidence & Outcomes, Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
2
Chambers-Grundy Center for Transformative Neuroscience, University of Nevada, Las Vegas (UNLV), Las Vegas, Nevada, USA.
3
Product Development, Patient-Centered Outcomes Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
PMID:
39692602
DOI:
10.1002/alz.14436
No abstract available
Grants and funding
F. Hoffmann-La Roche Ltd